The Rheumatoid Arthritis Market trajectory reflects a robust commitment to addressing joint destruction through cutting-edge therapeutic innovation. With methotrexate remaining the first-line DMARD and biologics commanding over 84% of the therapeutics market share, the clinical need for advanced interventions continues to intensify. The market benefits from a well-established regulatory...